https://scholars.lib.ntu.edu.tw/handle/123456789/527410
標題: | Clinical experience with open-Label topiramate use in epileptic children with CNS anomalies | 作者: | Yang M.-T. WANG-TSO LEE Yang Y.-J. Chang W.-C. Lian J.-S. |
關鍵字: | Central nervous system malformations; Child; Epilepsy; Hypohidrosis; Topiramate | 公開日期: | 2010 | 出版社: | Japan Epilepsy Society | 卷: | 3 | 期: | 1 | 起(迄)頁: | 84-95 | 來源出版物: | Epilepsy and Seizure | 摘要: | Purpose: To investigate the effectiveness and tolerability of topiramate (TPM) in treating children with CNS anomalies and intractable epilepsy. Methods: We retrospectively searched the patient database in National Taiwan University Hospital for candidate children (younger than 18 years of age) with epilepsy and CNS anomalies from December 2002 to February 2004. The effectiveness and possible side effects of TPM were evaluated by questionnaire. Results: Twenty-two children (9 males, 13 females) aged from five months to fourteen years were enrolled in the present study. Underlying CNS anomalies were proliferation disorders (n=10), migration/organization disorders (n=10), and neurocutaneous syndromes (n=2). Types of epilepsy at TPM add-on were symptomatic partial epilepsy (n=11), infantile spasms (n=7), and Lennox-Gastaut syndrome (n=4). During the follow-up periods of six to 30 months, eight patients (36%) had more than 50% reduction of seizures and four patients (18%) were seizure–free. The average dosages of TPM ranged from 2.5 to 25 mg/kg/day. Patients with proliferation disorders or infantile spasms responded better to TPM therapy. The most common side effect was oligohidrosis (n=9, 41%). Conclusion: TPM is a safe and promising add-on anticonvulsant for epileptic children with CNS anomalies. Hypohidrosis is one of the major side effects of TPM treatment. ? 2010, Japan Epilepsy Society. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85053385078&doi=10.3805%2feands.3.84&partnerID=40&md5=8745f60ce2bdd3a92d7b2fcf877cb3db https://scholars.lib.ntu.edu.tw/handle/123456789/527410 |
ISSN: | 1882-5567 | DOI: | 10.3805/eands.3.84 | SDG/關鍵字: | topiramate; abnormally high substrate concentration in blood; add on therapy; adolescent; aggressiveness; amnesia; anhidrosis; anorexia; anxiety; anxiety disorder; Article; ataxia; attention deficit disorder; body weight loss; central nervous system malformation; child; clinical article; clinical effectiveness; consciousness disorder; controlled study; data base; diplopia; dizziness; drug dose increase; drug dose titration; drug tolerability; drug withdrawal; dysarthria; female; focal epilepsy; follow up; headache; human; hyperactivity; infant; infantile spasm; Lennox Gastaut syndrome; lethargy; male; nausea; oligohidrosis; phakomatosis; pilot study; questionnaire; restlessness; retrospective study; sleep disorder; somnolence; speech disorder; sweat gland disease; Taiwan; tremor; university hospital; violence; vomiting; weakness |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。